The U.S. Food and Drug Administration today approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults....
The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular...
The U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic...
This week, the U.S. Department of Health and Human Services (HHS) issued the first Project BioShield contract to fund the advanced development needed to support the expanded use of an existing antibiotic...
Staphylococcus aureus is a major human pathogen prone to developing antibiotic resistance, causing 120,000 cases of bloodstream infections every year in the United States and over 5000 in Australia; the...
Once rare, the superbug methicillin-resistant Staphylococcus aureus (MRSA) infects hundreds of thousands of people in the U.S. each year and kills about 20,000. Antibiotic overuse has made MRSA more common...
Viral hepatitis is a disease that causes inflammation of the liver. There are three viruses responsible for most cases of the disease: hepatitis A, B, and C. Hepatitis A is typically caused by consuming...
The U.S. Food and Drug Administration today approved Fetroja (cefiderocol), an antibacterial drug for treatment of patients 18 years of age or older with complicated urinary tract infections (cUTI), including...
Tychan‘s first-in-class monoclonal antibody candidate treatment for Yellow Fever (YF), called TY014, has successfully completed Phase 1A/1B safety trials in Singapore, it announced today. Tychan...
Specialty biopharmaceutical company, RedHill Biopharma Ltd announced that the U.S. Food and Drug Administration (FDA) has approved Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release...
This website uses cookies to provide you with the best browsing experience.
Find out more or adjust your settings.
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
